公开(公告)号：WO2022006447A1

公开(公告)日：2022-01-06

申请号：PCT/US2021/040171

申请日：2021-07-01

申请人： THE TRUSTEES OF PRINCETON UNIVERSITY

发明人： GITAI, Zemer ,  KIM, Hahn ,  MARTIN, James K. ,  SHEEHAN, Joseph P. ,  RABINOWITZ, Joshua D. ,  XU, Xincheng ,  CHAIN, Connor

IPC分类号： C07D487/02 ,  A61P35/00

摘要： In one aspect, compounds and associated pharmaceutical compositions are described herein for the treatment of cancer. In some embodiments, for example, a pharmaceutical composition comprises a compound of Formula (I) in an amount sufficient to exhibit anti cancer activity.

公开(公告)号：WO2020041662A1

公开(公告)日：2020-02-27

申请号：PCT/US2019/047830

申请日：2019-08-23

申请人： THE TRUSTEES OF PRINCETON UNIVERSITY ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  O'CONNOR, Roderick

发明人： O'CONNOR, Roderick ,  RABINOWITZ, Joshua D.

IPC分类号： C12N9/82 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783 ,  A61K39/00

摘要： The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to the subject a population of immune cells that express an enzyme that facilitates immune cell function in a nutrient-poor environment. The invention also provides, in other embodiments, compositions comprising an ex vivo population of immune cells expressing an enzyme that enhances immune cell function in a nutrient-poor environment.

公开(公告)号：WO2022066864A1

公开(公告)日：2022-03-31

申请号：PCT/US2021/051691

申请日：2021-09-23

申请人： THE TRUSTEES OF PRINCETON UNIVERSITY

发明人： KIM, Hahn ,  RABINOWITZ, Joshua D.

IPC分类号： A61P37/00 ,  C07D491/052

摘要： Provided herein is a compound of the following structural formula: or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein. Also provided herein are compositions comprising a compound of structural formula (I), or a pharmaceutically acceptable salt thereof, and methods of treating a disease, disorder or condition associated with serine hydroxymethyl transferase (SHMT) activity, e.g., cancer, an autoimmune disorder, fibrosis and/or a fibrotic disease, in a subject in need thereof with a compound of structural formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2021142132A1

公开(公告)日：2021-07-15

申请号：PCT/US2021/012516

申请日：2021-01-07

申请人： THE TRUSTEES OF PRINCETON UNIVERSITY

发明人： RABINOWITZ, Joshua D. ,  YANG, Lifeng

IPC分类号： A61K31/155 ,  A61K31/35 ,  A61K31/00 ,  A61K31/352 ,  A61K31/365 ,  A61K31/454 ,  A61K45/06 ,  A61P11/00 ,  A61P9/10

摘要： The present disclosure relates, in various embodiments, to methods of treating various NADH-mediated diseases and disorders in a subject, such as disorders characterized by excess NADH, for example, by inhibiting serine catabolism in the subject.